Conceptio › Archive › Google Patents

Google Patentsopen access

Delivery, use and therapeutic applications of the crispr-cas systems and … — The Broad Institute, Inc. (US20250381297A1)

The Broad Institute, Inc. · Google Patents

Google Patents · Patents · License: Open Access

Open Source ↗

thebroadinstitute

patent, google patents, intellectual property, US20250381297A1, The Broad Institute, Inc., Sangeeta Bhatia, en, 2025

ABSTRACT

Abstract

The invention provides for delivery, engineering and optimization of systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are delivery systems and tissues or organ which are targeted as sites for delivery. Also provided are vectors and vector systems some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells to ensure enhanced specificity for target recognition and avoidance of toxicity and to edit or modify a target site in a genomic locus of interest to alter or improve the status of a disease or a condition.

Description

RELATED APPLICATIONS AND INCORPORATION BY REFERENCE

This application is a Continuation of U.S. application Ser. No. 17/002,262, filed on Aug. 25, 2020, now U.S. Pat. No. 12,251,450, that issued on Mar. 18, 2025, which is a Continuation of U.S. application Ser. No. 15/179,938, filed on Jun. 10, 2016, which is a Continuation-in-Part of International Application Number PCT/US14/70135, filed on Dec. 12, 2014, which published as PCT Publication No. WO2015/089465 on Jun. 18, 2015. This application claims priority from U.S. provisional application 61/915,301, filed Dec. 12, 2013, and U.S. provisional application 62/010,329, filed Jun. 10, 2014.

The foregoing application(s), and all documents cited therein or during its or their prosecution (âappln cited documentsâ) and all documents cited or referenced in the appln cited documents, and all documents cited or referenced herein (âherein cited documentsâ), and all documents cited or referenced in herein cited documents, together with any manufacturer's instructions, descriptions, product specifications, and product sheets for any products mentioned herein or in any document incorporated by reference herein, are hereby incorporated herein by reference, and may be employed in the practice of the invention. More specifically, all referenced documents are incorporated by reference to the same extent as if each individual document was specifically and individually indicated to be incorporated by reference.

STATEMENT AS TO FEDERALLY SPONSORED RESEARCH

This invention was made with government support under Grant No. MH100706 awarded by the National Institutes of Health. The government has certain rights in the invention.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has been submitted electronically in XML format and is hereby incorporated by reference in its entirety. Said XML copy created on Jul. 2, 2025, is named 114203-5906_SL.xml and is 2,174,197 bytes in size.

FIELD OF THE INVENTION

The present invention generally relates to the delivery, engineering, optimization and therapeutic applications of systems, methods, and compositions used for the control of gene expression involving sequence targeting, such as genome perturbation or gene-editing, that relate to Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and components thereof.

BACKGROUND OF THE INVENTION

Recent advances in genome sequencing techniques and analysis methods have significantly accelerated the ability to catalog and map genetic factors associated with a diverse range of biological functions and diseases. Precise genome targeting technologies are needed to enable systematic reverse engineering of causal genetic variations by allowing selective perturbation of individual genetic elements, as well as to advance synthetic biology, biotechnological, and medical applications. Although genome-editing techniques such as designer zinc fingers, transcription activator-like effectors (TALEs), or homing meganucleases are available for producing targeted genome perturbations, there remains a need for new genome engineering technologies that are affordable, easy to set up, scalable, and amenable to targeting multiple positions within the eukaryotic genome.

SUMMARY OF THE INVENTION

The CRISPR-Cas system does not require the generation of customized proteins to target specific sequences but rather a single Cas enzyme can be programmed by a short RNA molecule to recognize a specific DNA target. Adding the CRISPR-Cas system to the repertoire of genome sequencing techniques and analysis methods may significantly simplify the methodology and accelerate the ability to catalog and map genetic factors associated with a diverse range of biological functions and diseases. To utilize the CRISPR-Cas system effectively for genome editing without deleterious effects, it is critical to understand aspects of engineering, optimization and cell-type/tissue/organ specific delivery of these genome engineering tools, which are aspects of the claimed invention.

There exists a pressing need for alternative and robust systems and techniques for nucleic sequence targeting with a wide array of applications. Aspects of this invention address this need and provide related advantages, particularly in relation to treatment of viral infections which persist due to integration of a virus into a host's genome and/or by maintenance of an episomal form (e.g. hepatitis B virus, HBV, which maintains extraordinary persistence in the nucleus of human hepatocytes by means of a long-lived episomal double-stranded DNA form called covalent closed circular DNA, or cccDNA). Applicants have shown that it is possible to directly cleave and reduce the abundance of this episomal form of the virus (cccDNA: a dsDNA structure that arises during the propagation of HBV in the cell nucleus and can remain permanently present in infected subjects).

An exemplary CRISPR complex comprises a CRISPR enzyme complexed with a guide sequence hybridized or hybridizable to a target sequence within the target polynucleotide. The guide sequence is linked to a tracr mate sequence, which in turn hybridizes to a tracr sequence.

In one aspect, the invention provides methods for using one or more elements of a CRISPR-Cas system. The CRISPR complex of the invention provides an effective means for modifying a target polynucleotide. The CRISPR complex of the invention has a wide variety of utilities including modifying (e.g., deleting, inserting, translocating, inactivating, activating) a target polynucleotide in a multiplicity of cell types in various tissues and organs. As such the CRISPR complex of the invention has a broad spectrum of applications in, e.g., gene or genome editing, gene therapy, drug discovery, drug screening, disease diagnosis, and prognosis.

Aspects of the invention relate to Cas9 enzymes having improved targeting specificity in a CRISPR-Cas9 system having guide RNAs having optimal activity, smaller in length than wild-type Cas9 enzymes and nucleic acid molecules coding therefor, and chimeric Cas9 enzymes, as well as methods of improving the target specificity of a Cas9 enzyme or of designing a CRISPR-Cas9 system comprising designing or preparing guide RNAs having optimal activity and/or selecting or preparing a Cas9 enzyme having a smaller size or length than wild-type Cas9 whereby packaging a nucleic acid coding therefor into a delivery vector is more advanced as there is less coding therefor in the delivery vector than for wild-type Cas9, and/or generating chimeric Cas9 enzymes.

Also provided are uses of the present sequences, vectors, enzymes or systems, in medicine. Also provided are uses of the same in gene or genome editing.

In an additional aspect of the invention, a Cas9 enzyme may comprise one or more mutations and may be used as a generic DNA binding protein with or without fusion to a functional domain. The mutations may be artificially introduced mutations or gain- or loss-of-function mutations. The mutations may include but are not limited to mutations in one of the catalytic domains (D10 and H840) in the RuvC and HNH catalytic domains, respectively. Further mutations have been characterized. In one aspect of the invention, the transcriptional activation domain may be VP64. In other aspects of the invention, the transcriptional repressor domain may be KRAB or SID4X. Other aspects of the invention relate to the mutated Cas9 enzyme being fused to domains which include but are not limited to a transcriptional activator, repressor, a recombinase, a transposase, a histone remodeler, a demethylase, a DNA methyltransferase, a cryptochrome, a light inducible/controllable domain or a chemically inducible/controllable domain.

In a further embodiment, the invention provides for methods to generate mutant tracrRNA and direct repeat sequences or mutant chimeric guide sequences that allow for enhancing performance of these RNAs in cells. Aspects of the invention also provide for selection of said sequences.

Aspects of the invention also provide for methods of simplifying the cloning and delivery of components of the CRISPR complex. In the preferred embodiment of the invention, a suitable promoter, such as the U6 promoter, is amplified with a DNA oligo and added onto the guide RNA. The resulting PCR product can then be transfected into cells to drive expression of the guide RNA. Aspects of the invention also relate to the guide RNA being transcribed in vitro or ordered from a synthesis company and directly transfected.

In one aspect, the invention provides for methods to improve activity by using a more active polymerase. In a preferred embodiment, the expression of guide RNAs under the control of the T7 promoter is driven by the expression of the T7 polymerase in the cell. In an advantageous embodiment, the cell is a eukaryotic cell. In a preferred embodiment the eukaryotic cell is a human cell. In a more preferred embodiment the human cell is a patient specific cell, e.g., a cell removed from a patient that may be modified and/or expanded into a cell population or a modified cell population, for instance, for re-administration to the patient . . .

In one aspect, the invention provides for methods of reducing the toxicity of Cas enzymes. In certain aspects, the Cas enzyme is any Cas9 as described herein, for instance any naturally-occurring bacterial Cas9 as well as any chimaeras, mutants, homologs or orthologs. In one aspect, the Cas enzyme is a nickase. In a preferred embodiment, the Cas9 is delivered into the cell in the form of mRNA. This allows for the transient expression of the enzyme thereby reducing toxicity. In another embodiment, the Cas9 is delivered into the cell in the nucleotide construct that encodes and expresses the Cas9 enzyme. In another preferred embodiment, the invention also provides for methods of expressing Cas9 under the control of an inducible promoter, and the constructs used therein.

In another aspect, the invention provides for methods of improving the in vivo applications of the CRISPR-Cas system. In the preferred embodiment, the Cas enzyme is wildtype Cas9 or any of the modified versions described herein, including any naturally-occurring bacterial Cas9 as well as any chimaeras, mutants, homologs or orthologs. In some methods of the invention the CRISPR enzyme comprises one or more mutations in one of the catalytic domains. In one aspect, the Cas enzyme is a nickase. An advantageous aspect of the invention provides for the selection of Cas9 homologs that are easily packaged into viral vectors for delivery. Cas9 orthologs typically share the general organization of 3-4 RuvC domains and a HNH domain. The 5â² most RuvC domain cleaves the non-complementary strand, and the HNH domain cleaves the complementary strand. All notations are in reference to the guide sequence.

The catalytic residue in 5â² RuvC domain is identified through homology comparison of the Cas9 of interest with other Cas9 orthologs (from S. pyogenes type II CRISPR locus, S. thermophilus CRISPR locus 1, S. thermophilus CRISPR locus 3, and Franciscilla novicida type II CRISPR locus), and the conserved Asp residue (D10) is mutated to alanine to convert Cas9 into a complementary-strand nicking enzyme. Similarly, the conserved His and Asn residues in the HNH domains are mutated to Alanine to convert Cas9 into a non-complementary-strand nicking enzyme. In some embodiments, both sets of mutations may be made, to convert Cas9 into a non-cutting enzyme.

In some embodiments, the CRISPR enzyme is a type I or III CRISPR enzyme, preferably a type II CRISPR enzyme. This type II CRISPR enzyme may be any Cas enzyme. A preferred Cas enzyme may be identified as Cas9 as this can refer to the general class of enzymes that share homology to the biggest nuclease with multiple nuclease domains from the type II CRISPR system. Most preferably, the Cas9 enzyme is from, or is derived from, spCas9 or saCas9. By derived, Applicants mean that the derived enzyme is largely based, in the sense of having a high degree of sequence homology with, a wildtype enzyme, but that it has been mutated (modified) in some way as described herein

It will be appreciated that the terms Cas and CRISPR enzyme are generally used herein interchangeably, unless otherwise apparent. As mentioned above, many of the residue numberings used herein refer to the Cas9 enzyme from the type II CRISPR locus in Streptococcus pyogenes . However, it will be appreciated that this invention includes many more Cas9s from other species of microbes, such as SpCas9, SaCas9, StlCas9 and so forth. Further examples are provided herein. The skilled person will be able to determine appropriate corresponding residues in Cas9 enzymes other than SpCas9 by comparison of the relevant amino acid sequences. Thus, where a specific amino acid replacement is referred to using the SpCas9 numbering, then, unless the context makes it apparent this is not intended to refer to other Cas9 enzymes, the disclosure is intended to encompass corresponding modifications in other Cas9 enzymes.

An example of a codon optimized sequence, in this instance optimized for humans (i.e. being optimized for expression in humans) is provided herein, see the SaCas9 human codon optimized sequence. Whilst this is preferred, it will be appreciated that other examples are possible and codon optimization for a host species is known.

In further embodiments, the invention provides for methods of enhancing the function of Cas9 by generating chimeric Cas9 proteins. Chimeric Cas9 proteins chimeric Cas9s may be new Cas9 containing fragments from more than one naturally occurring Cas9. These methods may comprise fusing N-terminal fragments of one Cas9 homolog with C-terminal fragments of another Cas9 homolog. These methods also allow for the selection of new properties displayed by the chimeric Cas9 proteins.

It will be appreciated that in the present methods, where the organism is an animal or a plant, the modification may occur ex vivo or in vitro, for instance in a cell culture and in some instances not in vivo. In other embodiments, it may occur in vivo.

In one aspect, the invention provides a method of modifying an organism or a non-human organism by manipulation of a target sequence in a genomic locus of interest (e.g. an integrated viral sequence) comprising:

delivering a non-naturally occurring or engineered composition comprising:

A)âI. a CRISPR-Cas system chimeric RNA (chiRNA) polynucleotide sequence, wherein the polynucleotide sequence comprises:

(a) a guide sequence capable of hybridizing to a target sequence in a eukaryotic cell, (b) a tracr mate sequence, and (c) a tracr sequence, and

II. a polynucleotide sequence encoding a CRISPR enzyme comprising at least one or more nuclear localization sequences,

wherein (a), (b) and (c) are arranged in a 5â² to 3â² orientation, wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of a CRISPR complex to the target sequence, and wherein the CRISPR complex comprises the CRISPR enzyme complexed with (1) the guide sequence that is hybridized or hybridizable to the target sequence, and (2) the tracr mate sequence that is hybridized or hybridizable to the tracr sequence

RELATED APPLICATIONS AND INCORPORATION BY REFERENCE

STATEMENT AS TO FEDERALLY SPONSORED RESEARCH

This invention was made with government support under Grant No. MH100706 awarded by the National Institutes of Health. The government has certain rights in the invention.

SEQUENCE LISTING

FIELD OF THE INVENTION

BACKGROUND OF THE INVENTION

SUMMARY OF THE INVENTION

Also provided are uses of the present sequences, vectors, enzymes or systems, in medicine. Also provided are uses of the same in gene or genome editing.

delivering a non-naturally occurring or engineered composition comprising:

A)âI. a CRISPR-Cas system chimeric RNA (chiRNA) polynucleotide sequence, wherein the polynucleotide sequence comprises:

(a) a guide sequence capable of hybridizing to a target sequence in a eukaryotic cell, (b) a tracr mate sequence, and (c) a tracr sequence, and

II. a polynucleotide sequence encoding a CRISPR enzyme comprising at least one or more nuclear localization sequences,

(B) I. polynucleotides comprising:

(a) a guide sequence capable of hybridizing to a target sequence in a eukaryotic cell, and (b) at least one or more tracr mate sequences,

II. a polynucleotide sequence encoding a CRISPR enzyme, and III. a polynucleotide sequence comprising a tracr sequence,

wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of a CRISPR complex to the target sequence, and wherein the CRISPR complex comprises the CRISPR enzyme complexed with (1) the guide sequence that is hybridized or hybridizable to the target sequence, and (2) the tracr mate sequence that is hybridized or hybridizable to the tracr sequence, and the polynucleotide sequence encoding a CRISPR enzyme is DNA or RNA.

Any or all of the polynucleotide sequence encoding a CRISPR enzyme, guide sequence, tracr mate sequence or tracr sequence, may be RNA. The polynucleotides encoding the sequence encoding a CRISPR enzyme, the guide sequence, tracr mate sequence or tracr sequence may be RNA and may be delivered via liposomes, nanoparticles, exosomes, microvesicles, or a gene-gun.

It will be appreciated that where reference is made to a polynucleotide, which is RNA and is said to âcompriseâ a feature such a tracr mate sequence, the RNA sequence includes the feature. Where the polynucleotide is DNA and is said to comprise a feature such a tracr mate sequence, the DNA sequence is or can be transcribed into the RNA including the feature at issue. Where the feature is a protein, such as the CRISPR enzyme, the DNA or RNA sequence referred to is, or can be, translated (and in the case of DNA transcribed first).

Accordingly, in certain embodiments the invention provides a method of modifying an organism, e.g., mammal including human or a non-human mammal or organism by manipulation of a target sequence in a genomic locus of interest comprising delivering a non-naturally occurring or engineered composition comprising a viral or plasmid vector system comprising one or more viral or plasmid vectors operably encoding a composition for expression thereof, wherein the composition comprises: (A) a non-naturally occurring or engineered composition comprising a vector system comprising one or more vectors comprising I. a first regulatory element operably linked to a CRISPR-Cas system chimeric RNA (chiRNA) polynucleotide sequence, wherein the polynucleotide sequence comprises (a) a guide sequence capable of hybridizing to a target sequence in a eukaryotic cell, (b) a tracr mate sequence, and (c) a tracr sequence, and II. a second regulatory element operably linked to an enzyme-coding sequence encoding a CRISPR enzyme comprising at least one or more nuclear localization sequences (or optionally at least one or more nuclear localization sequences as some embodiments can involve no NLS), wherein (a), (b) and (c) are arranged in a 5â² to 3â² orientation, wherein components I and II are located on the same or different vectors of the system, wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of a CRISPR complex to the target sequence, and wherein the CRISPR complex comprises the CRISPR enzyme complexed with (1) the guide sequence that is hybridized or hybridizable to the target sequence, and (2) the tracr mate sequence that is hybridized or hybridizable to the tracr sequence, or (B) a non-naturally occurring or engineered composition comprising a vector system comprising one or more vectors comprising I. a first regulatory element operably linked to (a) a guide sequence capable of hybridizing to a target sequence in a eukaryotic cell, and (b) at least one or more tracr mate sequences, II. a second regulatory element operably linked to an enzyme-coding sequence encoding a CRISPR enzyme, and III. a third regulatory element operably linked to a tracr sequence, wherein components I, II and III are located on the same or different vectors of the system, wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of a CRISPR complex to the target sequence, and wherein the CRISPR complex comprises the CRISPR enzyme complexed with (1) the guide sequence that is hybridized or hybridizable to the target sequence, and (2) the tracr mate sequence that is hybridized or hybridizable to the tracr sequence. In some embodiments, components I, II and III are located on the same vector. In other embodiments, components I and II are located on the same vector, while component III is located on another vector. In other embodiments, components I and III are located on the same vector, while component II is located on another vector. In other embodiments, components II and III are located on the same vector, while component I is located on another vector. In other embodiments, each of components I, II and III is located on different vectors. The invention also provides a viral or plasmid vector system as described herein.

Preferably, the vector is a viral vector, such as a lenti- or baculo- or preferably adeno-viral/adeno-associated viral vectors, but other means of delivery are known (such as yeast systems, microvesicles, gene guns/means of attaching vectors to gold nanoparticles) and are provided. In some embodiments, one or more of the viral or plasmid vectors may be delivered via liposomes, nanoparticles, exosomes, microvesicles, or a gene-gun.

By manipulation of a target sequence, Applicants also mean the epigenetic manipulation of a target sequence. This may be of the chromatin state of a target sequence, such as by modification of the methylation state of the target sequence (i.e. addition or removal of methylation or methylation patterns or CpG islands), histone modification, increasing or reducing accessibility to the target sequence, or by promoting 3D folding. In relation to treatment of viral infections, however, excision of integrated viral genome sequences is the manipulation of primary interest.

It will be appreciated that where reference is made to a method of modifying an organism or mammal including human or a non-human mammal or organism by manipulation of a target sequence in a genomic locus of interest, this may apply to the organism (or mammal) as a whole or just a single cell or population of cells from that organism. In the case of humans, for instance, Applicants envisage, inter alia, a single cell or a population of cells and these may preferably be modified ex vivo and then re-introduced. In this case, a biopsy or other tissue or biological fluid sample may be necessary. Stem cells are also particularly preferred in this regard. But, of course, in vivo embodiments are also envisaged.

In certain embodiments the invention provides a method of treating or inhibiting a condition caused by the presence of an integrated viral sequence in a genomic locus of interest in a subject (e.g., mammal or human) or a non-human subject (e.g., mammal) in need thereof comprising modifying the subject or a non-human subject by manipulation of a target sequence in the integrated viral sequence and wherein the condition is susceptible to treatment or inhibition by manipulation of the target sequence comprising providing treatment comprising: delivering a non-naturally occurring or engineered composition comprising an AAV or lentivirus vector system comprising one or more AAV or lentivirus vectors operably encoding a composition for expression thereof, wherein the target sequence is manipulated by the composition when expressed, wherein the composition comprises: (A) a non-naturally occurring or engineered composition comprising a vector system comprising one or more vectors comprising I. a first regulatory element operably linked to a CRISPR-Cas system chimeric RNA (chiRNA) polynucleotide sequence, wherein the polynucleotide sequence comprises (a) a guide sequence capable of hybridizing to a target sequence in a eukaryotic cell, (b) a tracr mate sequence, and (c) a tracr sequence, and II. a second regulatory element operably linked to an enzyme-coding sequence encoding a CRISPR enzyme comprising at least one or more nuclear localization sequences (or optionally at least one or more nuclear localization sequences as some embodiments can involve no NLS, i.e., there can be zero NLSs but advantageously there is greater than zero NLSs, such as one or more or advantageously two or more NLSs, and thus the invention comprehends embodiments wherein there is 0, 1, 2, 3, or more NLSs) wherein (a), (b) and (c) are arranged in a 5â² to 3â² orientation, wherein components I and II are located on the same or different vectors of the system, wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of a CRISPR complex to the target sequence, and wherein the CRISPR complex comprises the CRISPR enzyme complexed with (1) the guide sequence that is hybridized or hybridizable to the target sequence, and (2) the tracr mate sequence that is hybridized or hybridizable to the tracr sequence, or (B) a non-naturally occurring or engineered composition comprising a vector system comprising one or more vectors comprising I. a first regulatory element operably linked to (a) a guide sequence capable of hybridizing to a target sequence in a eukaryotic cell, and (b) at least one or more tracr mate sequences, II. a second regulatory element operably linked to an enzyme-coding sequence encoding a CRISPR enzyme, and III. a third regulatory element operably linked to a tracr sequence, wherein components I, II and III are located on the same or different vectors of the system, wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of a CRISPR complex to the target sequence, and wherein the CRISPR complex comprises the CRISPR enzyme complexed with (1) the guide sequence that is hybridized or hybridizable to the target sequence, and (2) the tracr mate sequence that is hybridized or hybridizable to the tracr sequence. In some embodiments, components I, II and III are located on the same vector. In other embodiments, components I and II are located on the same vector, while component III is located on another vector. In other embodiments, components I and III are located on the same vector, while component II is located on another vector. In other embodiments, components II and III are located on the same vector, while component I is located on another vector. In other embodiments, each of components I, II and III is located on different vectors. The invention also provides a viral (e.g. AAV or lentivirus) vector system as described herein. Delivery therefore can be via a vector, such as a viral vector, e.g., a recombinant viral vector delivery system; and, this system can be an AAV or lentivirus or derived from an AAV or a lentivirus (e.g., a recombinant AAV or lentivirus that expresses that which is foreign, heterologous or that which is not homologous or native to the virus may make some consider the virus âderived fromâ is parent virus). In some methods of the invention the viral vector is a lentivirus-derived vector. In some methods of the invention the viral vector is an Agrobacterium Ti or Ri plasmid for use in plants.

The organism or subject is a eukaryote (including mammal including human) or a non-human eukaryote or a non-human animal or a non-human mammal. In some embodiments, the organism or subject is a non-human animal, and may be an arthropod, for example, an insect, or may be a nematode. In some methods of the invention the organism or subject is a plant. In some methods of the invention the organism or subject is a mammal or a non-human mammal. A non-human mammal may be for example a rodent (preferably a mouse or a rat), an ungulate, or a primate. In some methods of the invention the organism or subject is a plant or algae, including microalgae, or is a fungus. In some methods of the invention the viral vector is an AAV or a lentivirus, and can be part of a vector system as described herein. In some methods of the invention the CRISPR enzyme is a Cas9. In some methods of the invention the expression of the guide sequence is under the control of the T7 promoter and is driven by the expression of T7 polymerase. In some methods of the invention the expression of the guide sequence is under the control of a U6 promoter. In some methods of the invention the CRISPR enzyme comprises one or more mutations in one of the catalytic domains. In some methods of the invention the CRISPR enzyme is a Cas9 nickase.

The invention in some embodiments comprehends a method of delivering a CRISPR enzyme comprising delivering to a cell a nucleic acid molecule, e.g., DNA, RNA, mRNA encoding the CRISPR enzyme. In some of these methods the CRISPR enzyme is a Cas9. This allows for the transient expression of the enzyme thereby reducing toxicity. In another embodiment, the Cas9 is delivered into the cell in the nucleotide construct that encodes and expresses the Cas9 enzyme.

The invention also provides methods of preparing the vector systems of the invention, in particular the viral vector systems as described herein. The invention in some embodiments comprehends a method of preparing the AAV of the invention comprising transfecting plasmid(s) containing or consisting essentially of nucleic acid molecule(s) coding for the AAV into AAV-infected cells, and supplying AAV rep and/or cap obligatory for replication and packaging of the AAV. In some embodiments the AAV rep and/or cap obligatory for replication and packaging of the AAV are supplied by transfecting the cells with helper plasmid(s) or helper virus(es). In some embodiments the helper virus is a poxvirus, adenovirus, herpesvirus or baculovirus. In some embodiments the poxvirus is a vaccinia virus. In some embodiments the cells are mammalian cells. And in some embodiments the cells are insect cells and the helper virus is baculovirus. In other embodiments, the virus is a lentivirus.

In plants, viral pathogens are often host-specific, but this is not always the case. For instance, citrus tristeza virus infects only a few species in the Citrus genus, whereas cucumber mosaic virus infects over 1000 species in 85 plant families. Plants have existing and induced defenses to resist most pathogens, but the invention offers new ways to clear viral infections from plants.

The invention further comprehends a composition of the invention or a CRISPR enzyme thereof (including or alternatively mRNA encoding the CRISPR enzyme) for use in medicine or in therapy. In some embodiments the invention comprehends a composition according to the invention or a CRISPR enzyme thereof (including or alternatively a nucleic acid molecule, e.g., mRNA encoding the CRISPR enzyme) for use in a method according to the invention. In some embodiments the invention provides for the use of a composition of the invention or a CRISPR enzyme thereof (including or alternatively mRNA encoding the CRISPR enzyme) in ex vivo gene or genome editing. In certain embodiments the invention comprehends use of a composition of the invention or a CRISPR enzyme thereof (including or alternatively mRNA encoding the CRISPR enzyme) in the manufacture of a medicament for ex vivo gene or genome editing or for use in a method according of the invention. The invention thus also envisions a CRISPR-Cas Complex or a component thereof of any of any description herein for use in delivery to and/or a method of treating tissue, or tissue containing cells having a viral infection, such as Hepatitis B Virus; or in preparing or formulating a medicament or pharmaceutical composition for such treatment.

The invention comprehends in some embodiments a composition of the invention or a CRISPR enzyme thereof (including or alternatively mRNA encoding the CRISPR enzyme), wherein the target sequence is flanked at its 3â² end by a 5â² motif termed a proto-spacer adjacent motif or PAM, especially where the Cas9 is (or is derived from) S. pyogenes or S. aureus Cas9. For example, a suitable PAM is 5â²-NRG or 5â²-NNGRR (where N is any Nucleotide) for SpCas9 or SaCas9 enzymes (or derived enzymes), respectively, as mentioned below. For S. pyrogenes Cas9 or derived enzymes, a suitable PAM is 5â²-NRG.

It will be appreciated that SpCas9 or SaCas9 are those from or derived from S. pyogenes or S. aureus Cas9.

Aspects of the invention comprehend improving the specificity of a CRISPR enzyme, e.g. Cas9, mediated gene targeting and reducing the likelihood of off-target modification by the CRISPR enzyme, e.g. Cas9. The invention in some embodiments comprehends a method of modifying an organism or a non-human organism by minimizing off-target modifications by manipulation of a first and a second target sequence on opposite strands of a DNA duplex in a genomic locus of interest in a cell comprising delivering a non-naturally occurring or engineered composition comprising:

I. a first CRISPR-Cas system chimeric RNA (chiRNA) polynucleotide sequence, wherein the first polynucleotide sequence comprises: (a) a first guide sequence capable of hybridizing to the first target sequence, (b) a first tracr mate sequence, and (c) a first tracr sequence, II. a second CRISPR-Cas system chiRNA polynucleotide sequence, wherein the second polynucleotide sequence comprises: (a) a second guide sequence capable of hybridizing to the second target sequence, (b) a second tracr mate sequence, and (c) a second tracr sequence, and III. a polynucleotide sequence encoding a CRISPR enzyme comprising at least one or more nuclear localization sequences and comprising one or more mutations, wherein (a), (b) and (c) are arranged in a 5 â² to 3â² orientation, wherein when transcribed, the first and the second tracr mate sequence hybridize to the first and second tracr sequence respectively and the first and the second guide sequence directs sequence-specific binding of a first and a second CRISPR complex to the first and second target sequences respectively, wherein the first CRISPR complex comprises the CRISPR enzyme complexed with (1) the first guide sequence that is hybridized or hybridizable to the first target sequence, and (2) the first tracr mate sequence that is hybridized or hybridizable to the first tracr sequence, wherein the second CRISPR complex comprises the CRISPR enzyme complexed with (1) the second guide sequence that is hybridized or hybridizable to the second target sequence, and (2) the second tracr mate sequence that is hybridized or hybridizable to the second tracr sequence, wherein the polynucleotide sequence encoding a CRISPR enzyme is DNA or RNA, and wherein the first guide sequence directs cleavage of one strand of the DNA duplex near the first target sequence and the second guide sequence directs cleavage of the other strand near the second target sequence inducing a double strand break, thereby modifying the organism or the non-human organism by minimizing off-target modifications. In one aspect, the first nick and the second nick in the DNA is offset relative to each other by at least one base pair of the duplex. In one aspect, the first nick and the second nick are offset relative to each other so that the resulting DNA break has a 3â² overhang. In one aspect, the first nick and the second nick are offset relative to each other so that the resulting DNA break has a 5 â² overhang. In one aspect, the first nick and the second nick are positioned relative to each other such that the overhang is at least 1 nucleotide (nt), at least 10 nt, at least 15 nt, at least 26 nt, at least 30 nt, at least 50 nt or more that at least 50 nt. Additional aspects of the invention comprising the resulting offset double nicked DNA strand can be appreciated by one skilled in the art, and exemplary uses of the double nick system are provided herein.

In some methods of the invention any or all of the polynucleotide sequence encoding the CRISPR enzyme, the first and the second guide sequence, the first and the second tracr mate sequence or the first and the second tracr sequence, is/are RNA. In further embodiments of the invention the polynucleotides encoding the sequence encoding the CRISPR enzyme, the first and the second guide sequence, the first and the second tracr mate sequence or the first and the second tracr sequence, is/are RNA and are delivered via liposomes, nanoparticles, exosomes, microvesicles, or a gene-gun. In certain embodiments of the invention, the first and second tracr mate sequence share 100% identity and/or the first and second tracr sequence share 100% identity. In some embodiments, the polynucleotides may be comprised within a vector system comprising one or more vectors. In preferred embodiments of the invention the CRISPR enzyme is a Cas9 enzyme, e.g. SpCas9. In an aspect of the invention the CRISPR enzyme comprises one or more mutations in a catalytic domain, wherein the one or more mutations are selected from the group consisting of D10A, E762A, H840A, N854A, N863A and D986A. In a highly preferred embodiment the CRISPR enzyme has the D10A mutation. In preferred embodiments, the first CRISPR enzyme has one or more mutations such that the enzyme is a complementary strand nicking enzyme, and the second CRISPR enzyme has one or more mutations such that the enzyme is a non-complementary strand nicking enzyme. Alternatively the first enzyme may be a non-complementary strand nicking enzyme, and the second enzyme may be a complementary strand nicking enzyme.

With respect to mutations of the CRISPR enzyme, when the enzyme is not SpCas9, mutations may be made at any or all residues corresponding to positions 10, 762, 840, 854, 863 and/or 986 of SpCas9 (which may be ascertained for instance by standard sequence comparison tools). In particular, any or all of the following mutations are preferred in SpCas9: D10A, E762A, H840A, N854A, N863A and/or D986A; as well as conservative substitution for any of the replacement amino acids is also envisaged. In an aspect the invention provides as to any or each or all embodiments herein-discussed wherein the CRISPR enzyme comprises at least one or more, or at least two or more mutations, wherein the at least one or more mutation or the at least two or more mutations is as to D10, E762, H840, N854, N863, or D986 according to SpCas9 protein, e.g., D10A, E762A, H840A, N854A, N863A and/or D986A as to SpCas9, or N580 according to SaCas9, e.g., N580A as to SaCas9, or any corresponding mutation(s) in a Cas9 of an ortholog to Sp or Sa, or the CRISPR enzyme comprises at least one mutation wherein at least H840 or N863A as to Sp Cas9 or N580A as to Sa Cas9 is mutated; e.g., wherein the CRISPR enzyme comprises H840A, or D10A and H840A, or D10A and N863A, according to SpCas9 protein, or any corresponding mutation(s) in a Cas9 of an ortholog to Sp protein or Sa protein.

In preferred methods of the invention the first guide sequence directing cleavage of one strand of the DNA duplex near the first target sequence and the second guide sequence directing cleavage of the other strand near the second target sequence results in a 5â² overhang. In embodiments of the invention 5â² overhang is at most 200 base pairs, preferably at most 100 base pairs, or more preferably at most 50 base pairs. In embodiments of the invention 5â² overhang is at least 26 base pairs, preferably at least 30 base pairs or more preferably 34-50 base pairs.

The invention in some embodiments comprehends a method of modifying an organism or a non-human organism by minimizing off-target modifications by manipulation of a first and a second target sequence on opposite strands of a DNA duplex in a genomic locus of interest in a cell comprising delivering a non-naturally occurring or engineered composition comprising a vector system comprising one or more vectors comprising

I. a first regulatory element operably linked to (a) a first guide sequence capable of hybridizing to the first target sequence, and (b) at least one or more tracr mate sequences, II. a second regulatory element operably linked to (a) a second guide sequence capable of hybridizing to the second target sequence, and (b) at least one or more tracr mate sequences, III. a third regulatory element operably linked to an enzyme-coding sequence encoding a CRISPR enzyme, and IV. a fourth regulatory element operably linked to a tracr sequence, wherein components I, II, III and IV are located on the same or different vectors of the system, when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the first and the second guide sequence direct sequence-specific binding of a first and a second CRISPR complex to the first and second target sequences respectively, wherein the first CRISPR complex comprises the CRISPR enzyme complexed with (1) the first guide sequence that is hybridized or hybridizable to the first target sequence, and (2) the tracr mate sequence that is hybridized or hybridizable to the tracr sequence, wherein the second CRISPR complex comprises the CRISPR enzyme complexed with (1) the second guide sequence that is hybridized or hybridizable to the second target sequence, and (2) the tracr mate sequence that is hybridized or hybridizable to the tracr sequence, wherein the polynucleotide sequence encoding a CRISPR enzyme is DNA or RNA, and wherein the first guide sequence directs cleavage of one strand of the DNA duplex near the first target sequence and the second guide sequence directs cleavage of the other strand near the second target sequence inducing a double strand break, thereby modifying the organism or the non-human organism by minimizing off-target modifications.

The invention also provides a vector system as described herein. The system may comprise one, two, three or four different vectors. Components I, II, III and IV may thus be located on one, two, three or four different vectors, and all combinations for possible locations of the components are herein envisaged, for example: components I, II, III and IV can be located on the same vector; components I, II, III and IV can each be located on different vectors; components I, II, II I and IV may be located on a total of two or three different vectors, with all combinations of locations envisaged, etc.

In some methods of the invention any or all of the polynucleotide sequence encoding the CRISPR enzyme, the first and the second guide sequence, the first and the second tracr mate sequence or the first and the second tracr sequence, is/are RNA. In further embodiments of the invention the first and second tracr mate sequence share 100% identity and/or the first and second tracr sequence share 100% identity. In preferred embodiments of the invention the CRISPR enzyme is a Cas9 enzyme, e.g. SpCas9. In an aspect of the invention the CRISPR enzyme comprises one or more mutations in a catalytic domain, wherein the one or more mutations are selected from the group consisting of D10A, E762A, H840A, N854A, N863A and D986A. In a highly preferred embodiment the CRISPR enzyme has the D10A mutation. In preferred embodiments, the first CRISPR enzyme has one or more mutations such that the enzyme is a complementary strand nicking enzyme, and the second CRISPR enzyme has one or more mutations such that the enzyme is a non-complementary strand nicking enzyme. Alternatively the first enzyme may be a non-complementary strand nicking enzyme, and the second enzyme may be a complementary strand nicking enzyme. In a further embodiment of the invention, one or more of the viral vectors are delivered via liposomes, nanoparticles, exosomes, microvesicles, or a gene-gun.

In preferred methods of the invention the first guide sequence directing cleavage of one strand of the DNA duplex near the first target sequence and the second guide sequence directing cleavage of other strand near the second target sequence results in a 5 â² overhang. In embodiments of the invention 5â² overhang is at most 200 base pairs, preferably at most 100 base pairs, or more preferably at most 50 base pairs. In embodiments of the invention 5â² overhang is at least 26 base pairs, preferably at least 30 base pairs or more preferably 34-50 base pairs.

The invention in some embodiments comprehends a method of modifying a genomic locus of interest by minimizing off-target modifications by introducing into a cell containing and expressing a double stranded DNA molecule encoding a gene product of interest an engineered, non-naturally occurring CRISPR-Cas system comprising a Cas protein having one or more mutations and two guide RNAs that target a first strand and a second strand of the DNA molecule respectively, whereby the guide RNAs target the DNA molecule encoding the gene product and the Cas protein nicks each of the first strand and the second strand of the DNA molecule encoding the gene product, whereby expression of the gene product is altered; and, wherein the Cas protein and the two guide RNAs do not naturally occur together.

In preferred methods of the invention the Cas protein nicking each of the first strand and the second strand of the DNA molecule encoding the gene product results in a 5 â² overhang. In embodiments of the invention 5â² overhang is at most 200 base pairs, preferably at most 100 base pairs, or more preferably at most 50 base pairs. In embodiments of the invention 5â² overhang is at least 26 base pairs, preferably at least 30 base pairs or more preferably 34-50 base pairs.

Embodiments of the invention also comprehend the guide RNAs comprising a guide sequence fused to a tracr mate sequence and a tracr sequence. In an aspect of the invention the Cas protein is codon optimized for expression in a eukaryotic cell, preferably a mammalian cell or a human cell. As explained in more detail below, codon usage can even be optimized for expression in particular cell types e.g. for liver cells. In further embodiments of the invention the Cas protein is a type II CRISPR-Cas protein, e.g. a Cas9 protein. In a highly preferred embodiment the Cas protein is a Cas9 protein, e.g. SpCas9. In aspects of the invention the Cas protein has one or more mutations selected from the group consisting of D10A, E762A, H840A, N854A, N863A and D986A. In a highly preferred embodiment the Cas protein has the D10A mutation.

The invention also comprehends an engineered, non-naturally occurring CRISPR-Cas system comprising a Cas protein having one or more mutations and two guide RNAs that target a first strand and a second strand respectively of a double stranded DNA molecule encoding a gene product in a cell, whereby the guide RNAs target the DNA molecule encoding the gene product and the Cas protein nicks each of the first strand and the second strand of the DNA molecule encoding the gene product, whereby expression of the gene product is altered; and, wherein the Cas protein and the two guide RNAs do not naturally occur together.

In aspects of the invention the guide RNAs may comprise a guide sequence fused to a tracr mate sequence and a tracr sequence. In an embodiment of the invention the Cas protein is a type II CRISPR-Cas protein. In an aspect of the invention the Cas protein is codon optimized for expression in a eukaryotic cell, preferably a mammalian cell or a human cell. In further embodiments of the invention the Cas protein is a type II CRISPR-Cas protein, e.g. a Cas9 protein. In a highly preferred embodiment the Cas protein is a Cas9 protein, e.g. SpCas9. In aspects of the invention the Cas protein has one or more mutations selected from the group consisting of D10A, E762A, H840A, N854A, N863A and D986A. In a highly preferred embodiment the Cas protein has the D10A mutation.

The invention also comprehends an engineered, non-naturally occurring vector system comprising one or more vectors comprising:

a) a first regulatory element operably linked to each of two CRISPR-Cas system guide RNAs that target a first strand and a second strand respectively of a double stranded DNA molecule encoding a gene product, b) a second regulatory element operably linked to a Cas protein,

wherein components (a) and (b) are located on same or different vectors of the system, whereby the guide RNAs target the DNA molecule encoding the gene product and the Cas protein nicks each of the first strand and the second strand of the DNA molecule encoding the gene product, whereby expression of the gene product is altered; and, wherein the Cas protein and the two guide RNAs do not naturally occur together.

Aspects of the invention relate to the expression of the gene product being decreased or a template polynucleotide being further introduced into the DNA molecule encoding the gene product or an intervening sequence being excised precisely by allowing the two 5â² overhangs to reanneal and ligate or the activity or function of the gene product being altered or the expression of the gene product being increased. In an embodiment of the invention, the gene product is a protein. In preferred embodiments of the invention the vectors of the system are viral vectors. In a further embodiment, the vectors of the system are delivered via liposomes, nanoparticles, exosomes, microvesicles, or a gene-gun.

In one aspect, the invention provides a method of modifying a target polynucleotide in a eukaryotic cell. In some embodiments, the method comprises allowing a CRISPR complex to bind to the target polynucleotide to effect cleavage of said target polynucleotide thereby modifying the target polynucleotide, wherein the CRISPR complex comprises a CRISPR enzyme complexed with a guide sequence hybridized or hybridizable to a target sequence within said target polynucleotide, wherein said guide sequence is linked to a tracr mate sequence which in turn hybridizes to a tracr sequence. In some embodiments, said cleavage comprises cleaving one or two strands at the location of the target sequence by said CRISPR enzyme. In some embodiments, said cleavage results in decreased transcription of a target gene. In some embodiments, the method further comprises repairing said cl

CLAIMS

Claims ( 20 )

1 - 33 . (canceled)

34 . A method of treating a hepatitis B virus (HBV) infection in a mammal, comprising administering an effective amount of a CRISPR-Cas system to the mammal, wherein the CRISPR-Cas system comprises

(i) a catalytically inactive CRISPR protein that is fused to a transcriptional repressor or a polynucleotide encoding a catalytically inactive CRISPR protein that is fused to a transcriptional repressor, (ii) a CRISPR-Cas system polynucleotide targeting a target HBV sequence comprised both in an HBV covalently closed circular DNA (cccDNA) and in an HBV DNA integrated into the genome of a liver cell, wherein the CRISPR-Cas system polynucleotide comprises:

(a) a guide sequence capable of hybridizing to the target HBV sequence,

(b) a tracr sequence, and

wherein the CRISPR-Cas system polynucleotide forms a CRISPR complex with the CRISPR protein in the liver cell and directs sequence-specific binding of the CRISPR complex to the target HBV sequence both in the HBV cccDNA and in the HBV DNA integrated into the genome of the liver cell,

thereby resulting in the transcriptional repressor repressing the expression of both the HBV cccDNA and the HBV DNA integrated into the genome of the liver cell and reducing HBsAg, serum HBV DNA and HBV RNA in vivo in the mammal.

35 . The method of claim 34 , wherein the catalytically inactive CRISPR protein further comprises a heterologous functional domain selected from a transcriptional activator, a transcriptional repressor, a recombinase, a transposase, a histone remodeler, a demethylase, or a DNA methyltransferase.

36 . The method of claim 35 , wherein the heterologous functional domain is a DNA methyltransferase.

37 . The method of claim 35 , wherein the heterologous functional domain is VP64, SID4X, or KRAB.

38 . The method of claim 34 , wherein the CRISPR protein further comprises one or more nuclear localization sequences (NLSs) capable of driving the accumulation of the CRISPR protein to a detectible amount in the nucleus of the liver cell.

39 . The method of claim 38 , wherein the CRISPR protein comprises at least one NLS at or near the amino-terminus of the CRISPR protein and/or at least one NLS at or near the carboxy-terminus the CRISPR protein.

40 . The method of claim 34 , wherein the CRISPR-Cas system is comprised in a liposome or a lipid particle.

41 . The method of claim 34 , wherein the CRISPR protein is Cas9.

42 . The method of claim 41 , wherein the CRISPR protein is Staphylococcus aureus Cas9.

43 . The method of claim 41 , wherein the CRISPR protein is Streptococcus pyogenes Cas9.

44 . The method of claim 34 , wherein the CRISPR protein and/or the CRISPR-Cas system polynucleotides are encoded or comprised within a vector system comprising one or more vectors.

45 . The method of claim 44 , wherein the one or more vectors comprise one or more viral vectors.

46 . The method of claim 45 , wherein the one or more viral vectors comprise one or more lentiviral, adenoviral or adeno-associated viral (AAV) vectors.

47 . The method of claim 34 , wherein the CRISPR-Cas system polynucleotide is a chimeric RNA (chiRNA).

48 . The method of claim 44 , wherein the CRISPR protein and the CRISPR-Cas system polynucleotides are encoded in a single vector.

49 . The method of claim 34 , further comprising administering an additional HBV treatment to the mammal.

50 . The method of claim 49 , wherein the additional treatment comprises an epigenetic modifier.

51 . The method of claim 50 , wherein the epigenetic modifier selected from trichostatin A (TSA), valproate, and nicotinamide (NAM), or Type I interferon.

52 . The method of claim 34 , wherein the mammal is a human subject.

US19/079,848

2013-12-12

2025-03-14

Delivery, use and therapeutic applications of the crispr-cas systems and compositions for hbv and viral diseases and disorders

Pending

US20250381297A1

( en )

Priority Applications (1)

Application Number

Priority Date

Filing Date

Title

US19/079,848

US20250381297A1

( en )

2013-12-12

2025-03-14

Delivery, use and therapeutic applications of the crispr-cas systems and compositions for hbv and viral diseases and disorders

Applications Claiming Priority (6)

Application Number

Priority Date

Filing Date

Title

US201361915301P

2013-12-12

US201462010329P

2014-06-10

PCT/US2014/070135

WO2015089465A1

( en )

2013-12-12

2014-12-12

Delivery, use and therapeutic applications of the crispr-cas systems and compositions for hbv and viral diseases and disorders

US15/179,938

US20160317677A1

( en )

2013-12-12

2016-06-10

Delivery, use and therapeutic applications of the crispr-cas systems and compositions for hbv and viral diseases and disorders

US17/002,262

US12251450B2

( en )

2013-12-12

2020-08-25

Delivery, use and therapeutic applications of the CRISPR-Cas systems and compositions for HBV and viral diseases and disorders

US19/079,848

US20250381297A1

( en )

2013-12-12

2025-03-14

Delivery, use and therapeutic applications of the crispr-cas systems and compositions for hbv and viral diseases and disorders

Related Parent Applications (1)

Application Number

Title

Priority Date

Filing Date

US17/002,262

Continuation

US12251450B2

( en )

2013-12-12

2020-08-25

Delivery, use and therapeutic applications of the CRISPR-Cas systems and compositions for HBV and viral diseases and disorders

Publications (1)

Publication Number

Publication Date

US20250381297A1

true

US20250381297A1 ( en )

2025-12-18

Family

ID=53371891

Family Applications (3)

Application Number

Title

Priority Date

Filing Date

US15/179,938

Abandoned

US20160317677A1

( en )

2013-12-12

2016-06-10

Delivery, use and therapeutic applications of the crispr-cas systems and compositions for hbv and viral diseases and disorders

US17/002,262

Active

2038-03-05

US12251450B2

( en )

2013-12-12

2020-08-25

Delivery, use and therapeutic applications of the CRISPR-Cas systems and compositions for HBV and viral diseases and disorders

US19/079,848

Pending

US20250381297A1

( en )

2013-12-12

2025-03-14

Delivery, use and therapeutic applications of the crispr-cas systems and compositions for hbv and viral diseases and disorders

Family Applications Before (2)

Application Number

Title

Priority Date

Filing Date

US15/179,938

Abandoned

US20160317677A1

( en )

2013-12-12

2016-06-10

Delivery, use and therapeutic applications of the crispr-cas systems and compositions for hbv and viral diseases and disorders

US17/002,262

Active

2038-03-05

US12251450B2

( en )

2013-12-12

2020-08-25

Delivery, use and therapeutic applications of the CRISPR-Cas systems and compositions for HBV and viral diseases and disorders

Country Status (13)

Country

Link

( 3 )

US20160317677A1

( en )

( 3 )

EP3080261B1

( en )

( 1 )

JP2017527256A

( en )

( 1 )

KR20160089530A

( en )

( 2 )

CN105899658B

( en )

( 1 )

AU2014361784A1

( en )

( 1 )

BR112016013207A2

( en )

( 1 )

CA2932479A1

( en )

( 1 )

IL246117B

( en )

( 1 )

MX374530B

( en )

( 1 )

RU2016128077A

( en )

( 1 )

SG10201804975PA

( en )

( 1 )

WO2015089465A1

( en )

Families Citing this family (236)

* Cited by examiner, â Cited by third party

Publication number

Priority date

Publication date

Assignee

Title

WO2013066438A2

( en )

2011-07-22

2013-05-10

President And Fellows Of Harvard College

Evaluation and improvement of nuclease cleavage specificity

EP3919505B1

( en )

2013-01-16

2023-08-30

Emory University

Uses of cas9-nucleic acid complexes

DK2986729T3

( en )

2013-04-16

2018-10-29

Regeneron Pharma

TARGETED MODIFICATION OF ROOT THROUGH

US20150044192A1

( en )

2013-08-09

2015-02-12

President And Fellows Of Harvard College

Methods for identifying a target site of a cas9 nuclease

US9359599B2

( en )

2013-08-22

2016-06-07

President And Fellows Of Harvard College

Engineered transcription activator-like effector (TALE) domains and uses thereof

US9526784B2

( en )

2013-09-06

2016-12-27

President And Fellows Of Harvard College

Delivery system for functional nucleases

US9388430B2

( en )

2013-09-06

2016-07-12

President And Fellows Of Harvard College

Cas9-recombinase fusion proteins and uses thereof

US9340799B2

( en )

2013-09-06

2016-05-17

President And Fellows Of Harvard College

MRNA-sensing switchable gRNAs

CN106459995B

( en )

2013-11-07

2020-02-21

ç±è¿ªå¡æ¯å»è¯æéå¬å¸

CRISPR-related methods and compositions using dominant gRNAs

WO2015088643A1

( en )

2013-12-11

2015-06-18

Regeneron Pharmaceuticals, Inc.

Methods and compositions for the targeted modification of a genome

US20150166984A1

( en )

2013-12-12

2015-06-18

President And Fellows Of Harvard College

Methods for correcting alpha-antitrypsin point mutations

EP3107999A4

( en )

2014-02-18

2017-10-04

Duke University

Compositions for the inactivation of virus replication and methods of making and using the same

EP3498845B1

( en )

2014-04-01

2022-06-22

Editas Medicine, Inc.

Crispr/cas-related methods and compositions for treating herpes simplex virus type 1 (hsv-1)

KR20170005494A

( en )

2014-05-30

2017-01-13

Compositions and methods of delivering treatments for latent viral infections

WO2016022363A2

( en )

2014-07-30

2016-02-11

President And Fellows Of Harvard College

Cas9 proteins including ligand-dependent inteins

US20170315110A1

( en )

2014-10-21

2017-11-02

The Trustees Of Princeton University

Systems and methods for personalized sample analysis

JP6788584B2

( en )

2014-10-31

2020-11-25

ããµãã¥ã¼ã»ãã ã¤ã³ã¹ãã£ãã¥ã¼ã ãªã ãã¯ããã¸ã¼

Massively Parallel Combinatorial Genetics on CRISPR

CA2968440A1

( en )

2014-11-21

2016-05-26

Regeneron Pharmaceuticals, Inc.

Methods and compositions for targeted genetic modification using paired guide rnas

US11168369B2

( en )

2014-11-25

2021-11-09

The Brigham And Women's Hospital, Inc.

Method of identifying and treating a person having a predisposition to or afflicted with a cardiometabolic disease

WO2016089433A1

( en )

2014-12-03

2016-06-09

Agilent Technologies, Inc.

Guide rna with chemical modifications

WO2016094872A1

( en )

2014-12-12

2016-06-16

The Broad Institute Inc.

Dead guides for crispr transcription factors

WO2016094874A1

( en )

2014-12-12

2016-06-16

The Broad Institute Inc.

Escorted and functionalized guides for crispr-cas systems

EP3230451B1

( en )

2014-12-12

2021-04-07

The Broad Institute, Inc.

Protected guide rnas (pgrnas)

WO2016100974A1

( en )

2014-12-19

2016-06-23

The Broad Institute Inc.

Unbiased identification of double-strand breaks and genomic rearrangement by genome-wide insert capture sequencing

WO2016106236A1

( en )

2014-12-23

2016-06-30

The Broad Institute Inc.

Rna-targeting system

CA2970370A1

( en )

2014-12-24

2016-06-30

Massachusetts Institute Of Technology

Crispr having or associated with destabilization domains

WO2016108926A1

( en )

2014-12-30

2016-07-07

The Broad Institute Inc.

Crispr mediated in vivo modeling and genetic screening of tumor growth and metastasis

MA41349A

( en )

2015-01-14

2017-11-21

Univ Temple

RNA-GUIDED ERADICATION OF HERPES SIMPLEX TYPE I AND OTHER ASSOCIATED HERPES VIRUSES

US10059940B2

( en )

2015-01-27

2018-08-28

Minghong Zhong

Chemically ligated RNAs for CRISPR/Cas9-lgRNA complexes as antiviral therapeutic agents

JP6929791B2

( en )

2015-02-09

2021-09-01

ãã¥ã¼ã¯ ã¦ããã¼ã·ãã£

Compositions and methods for epigenome editing

GB2536650A

( en )

2015-03-24

2016-09-28

Augmedics Ltd

Method and system for combining video-based and optic-based augmented reality in a near eye display

KR102888521B1

( en )

2015-04-06

2025-11-19

Chemically modified guide rnas for crispr/cas-mediated gene regulation

US10117911B2

( en )

2015-05-29

2018-11-06

Agenovir Corporation

Compositions and methods to treat herpes simplex virus infections

US20160346362A1

( en )

2015-05-29

2016-12-01

Agenovir Corporation

Methods and compositions for treating cytomegalovirus infections

US20180245074A1

( en )

2015-06-04

2018-08-30

Protiva Biotherapeutics, Inc.

Treating hepatitis b virus infection using crispr

WO2016197133A1

( en )

2015-06-04

2016-12-08

Protiva Biotherapeutics, Inc.

Delivering crispr therapeutics with lipid nanoparticles

AU2016279077A1

( en )

2015-06-18

2019-03-28

Omar O. Abudayyeh

Novel CRISPR enzymes and systems

EP3436575A1

( en )

2015-06-18

2019-02-06

The Broad Institute Inc.

Novel crispr enzymes and systems

CA2990699A1

( en )

2015-06-29

2017-01-05

Ionis Pharmaceuticals, Inc.

Modified crispr rna and modified single crispr rna and uses thereof

WO2017004191A1

( en )

2015-06-30

2017-01-05

Regents Of The University Of Minnesota

Transgenic mouse for expressing apobec3b

JP2017018026A

( en )

2015-07-09

2017-01-26

å½ç«ç ç©¶éçºæ³äººå»è¬åºç¤ã»å¥åº·ã»æ é¤ç ç©¶æ

Method for gene-targeting of pluripotent stem cells

WO2017015637A1

( en )

2015-07-22

2017-01-26

Duke University

High-throughput screening of regulatory element function with epigenome editing technologies

JP7602862B2

( en )

2015-07-25

2024-12-19

ãããã»ããã¹ã

Systems, devices and methods for providing treatment or cure for cancer and other pathological conditions

WO2017027810A2

( en )

2015-08-12

2017-02-16

The General Hospital Corporation

Compositions and methods that promote hypoxia or the hypoxia response for treatment and prevention of mitochondrial dysfunction and oxidative stress disorders

WO2017035416A2

( en )

2015-08-25

2017-03-02

Duke University

Compositions and methods of improving specificity in genomic engineering using rna-guided endonucleases

HK1258900A1

( en )

2015-09-29

2019-11-22

ååè¯ºç»´äºå¬å¸

Delivery methods and compositions

US20170087225A1

( en )

2015-09-29

2017-03-30

Agenovir Corporation

Compositions and methods for latent viral transcription regulation

AU2016335698B2

( en )

2015-10-08

2022-12-01

President And Fellows Of Harvard College

Multiplexed genome editing

EP4089175A1

( en )

2015-10-13

2022-11-16

Duke University

Genome engineering with type i crispr systems in eukaryotic cells

EP3365447A1

( en )

2015-10-21

2018-08-29

Editas Medicine, Inc.

Crispr/cas-related methods and compositions for treating hepatitis b virus

CN109153980B

( en )

2015-10-22

2023-04-14

å¸ç½å¾·ç ç©¶ææéå¬å¸

Type VI-B CRISPR enzymes and systems

SG10202104041PA

( en )

2015-10-23

2021-06-29

Harvard College

Nucleobase editors and uses thereof

JP7408284B2

( en )

2015-10-30

2024-01-05

ã¨ãã£ã¿ã¹ã»ã¡ãã£ã·ã³ãã¤ã³ã³ã¼ãã¬ã¤ããã

CRISPR/CAS-related methods and compositions for treating herpes simplex virus

US20180327781A1

( en )

2015-11-09

2018-11-15

Seattle Children's Hospital (dba Seattle Children's Research Institute)

Novel rna-based vector system for transient and stable gene expression

CA3005878A1

( en )

2015-11-19

2017-05-26

The Brigham And Women's Hospital, Inc.

Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity

US11427861B2

( en )

2016-03-17

2022-08-30

Massachusetts Institute Of Technology

Methods for identifying and modulating co-occurant cellular phenotypes

EP3219799A1

( en )

2016-03-17

2017-09-20

IMBA-Institut fÃ¼r Molekulare Biotechnologie GmbH

Conditional crispr sgrna expression

EP3443081A4

( en )

2016-04-13

2019-10-30

Duke University

CRISPR / CAS9-BASED REPRESSORS TO INACTIVATE IN VIVO GENE TARGETS AND METHODS OF USE

WO2017189964A2

( en )

2016-04-29

2017-11-02

Voyager Therapeutics, Inc.

Compositions for the treatment of disease

US11326182B2

( en )

2016-04-29

2022-05-10

Voyager Therapeutics, Inc.

Compositions for the treatment of disease

US20190093092A1

( en )

2016-05-05

2019-03-28

Temple University - Of The Commonwealth System Of Higher Education

Rna guided eradication of varicella zoster virus

US20170332610A1

( en )

2016-05-20

2017-11-23

Regeneron Pharmaceuticals, Inc.

Methods for breaking immunological tolerance using multiple guide rnas

US11371081B2

( en )

2016-05-25

2022-06-28

Arizona Board Of Regents On Behalf Of Arizona State University

Portable, low-cost pathogen detection and strain identification platform

WO2017210380A1

( en )

2016-06-01

2017-12-07

Excision Biotherapeutics, Inc.

Compositions and methods of treatment for lytic and lysogenic viruses

RU2771383C2

( en )

2016-06-03

2022-05-04

FOOD RATION-CONTROLLED EXPRESSION OF NUCLEIC ACID ENCODING Cas9 NUCLEASE, AND ITS APPLICATIONS

US10767175B2

( en )

2016-06-08

2020-09-08

Agilent Technologies, Inc.

High specificity genome editing using chemically modified guide RNAs

US12595478B2

( en )

2016-06-29

2026-04-07

The Broad Institute, Inc.

Crispr-Cas systems having destabilization domain

US11359234B2

( en )

2016-07-01

2022-06-14

Microsoft Technology Licensing, Llc

Barcoding sequences for identification of gene expression

EP3478852B1

( en )

2016-07-01

2020-08-12

Microsoft Technology Licensing, LLC

Storage through iterative dna editing

US20180004537A1

( en )

2016-07-01

2018-01-04

Microsoft Technology Licensing, Llc

Molecular State Machines

EP4275747A3

( en )

2016-07-19

2024-01-24

Duke University

Therapeutic applications of cpf1-based genome editing

KR20250103795A

( en )

2016-08-03

2025-07-07

íë ì§ëí¸ ì¤ë í ë¡ì°ì¦ ì¤ë¸ íë°ë ì¹¼ë¦¬ì§

Adenosine nucleobase editors and uses thereof

US11661590B2

( en )

2016-08-09

2023-05-30

President And Fellows Of Harvard College

Programmable CAS9-recombinase fusion proteins and uses thereof

WO2018035387A1

( en )

2016-08-17

2018-02-22

The Broad Institute, Inc.

Novel crispr enzymes and systems

WO2018035388A1

( en )

2016-08-17

2018-02-22

The Broad Institute, Inc.

Novel crispr enzymes and systems

WO2018039438A1

( en )

2016-08-24

2018-03-01

President And Fellows Of Harvard College

Incorporation of unnatural amino acids into proteins using base editing

KR101856345B1

( en )

2016-08-24

2018-06-20

ê²½ìëíêµì°ííë ¥ë¨

Method for generation of APOBEC3H and APOBEC3CH double-knocked out cat using CRISPR/Cas9 system

WO2018064208A1

( en )

2016-09-28

2018-04-05

The Broad Institute, Inc.

Systematic screening and mapping of regulatory elements in non-coding genomic regions, methods, compositions, and applications thereof

WO2018067991A1

( en )

2016-10-07

2018-04-12

The Brigham And Women's Hospital, Inc.

Modulation of novel immune checkpoint targets

FI3526323T3

( en )

2016-10-14

2023-06-06

Prec Biosciences Inc

Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome

SG11201903089RA

( en )

2016-10-14

2019-05-30

Harvard College

Aav delivery of nucleobase editors

WO2018089386A1

( en )

2016-11-11

2018-05-17

The Broad Institute, Inc.

Modulation of intestinal epithelial cell differentiation, maintenance and/or function through t cell action

CN110168102A

( en )

2016-11-15

2019-08-23

åºå ç»å½±åå¬å¸

The method of the gene editing event of modified nucleic acid enzyme induction is monitored using molecule combing

CN106729753A

( en )

2016-12-16

2017-05-31

è°æ

The delivery system and biological agent of anti-hepatitis B virus

WO2018119359A1

( en )

2016-12-23

2018-06-28

President And Fellows Of Harvard College

Editing of ccr5 receptor gene to protect against hiv infection

KR101796036B1

( en )

2016-12-29

2017-11-10

Delivery carrier composition comprising nanoliposome encapsulating complex of Cas9 protein, guide RNA for repressing gene expression or KRAS gene and cationic polymer, or therapeutics comprising thereof for treating KRAS mutation colon cancer with anticancer drug resistance

CN108342387B

( en )

2017-01-24

2021-09-24

è°æ

Delivery system and biological agent of PCSK9 inhibitor hypolipidemic drug

TW201839136A

( en )

2017-02-06

2018-11-01

çå£«åè«¾è¯å¬å¸

Composition and method for treating hemochromatosis

EP3592381A1

( en )

2017-03-09

2020-01-15

President and Fellows of Harvard College

Cancer vaccine

US11898179B2

( en )

2017-03-09

2024-02-13

President And Fellows Of Harvard College

Suppression of pain by gene editing

WO2018165629A1

( en )

2017-03-10

2018-09-13

President And Fellows Of Harvard College

Cytosine to guanine base editor

WO2018176009A1

( en )

2017-03-23

2018-09-27

President And Fellows Of Harvard College

Nucleobase editors comprising nucleic acid programmable dna binding proteins

WO2018175924A1

( en )

2017-03-24

2018-09-27

The Broad Institute, Inc.

Methods and compositions for regulating innate lymphoid cell inflammatory responses

US11963966B2

( en )

2017-03-31

2024-04-23

Dana-Farber Cancer Institute, Inc.

Compositions and methods for treating ovarian tumors

US20200071773A1

( en )

2017-04-12

2020-03-05

Massachusetts Eye And Ear Infirmary

Tumor signature for metastasis, compositions of matter methods of use thereof

WO2018191520A1

( en )

2017-04-12

2018-10-18

The Broad Institute, Inc.

Respiratory and sweat gland ionocytes

WO2018191558A1

( en )

2017-04-12

2018-10-18

The Broad Institute, Inc.

Modulation of epithelial cell differentiation, maintenance and/or function through t cell action, and markers and methods of use thereof

EP3612023A4

( en )

2017-04-20

2021-05-12

Egenesis, Inc.

GENETICALLY MODIFIED ANIMAL PRODUCTION PROCESSES

US12208140B2

( en )

2017-04-21

2025-01-28

The Broad Institute, Inc.

Targeted delivery to beta cells

WO2018204777A2

( en )

2017-05-05

2018-11-08

The Broad Institute, Inc.

Methods for identification and modification of lncrna associated with target genotypes and phenotypes

WO2018209324A2

( en )

2017-05-11

2018-11-15

The Broad Institute, Inc.

Methods and compositions of use of cd8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof

WO2018209320A1

( en )

2017-05-12

2018-11-15

President And Fellows Of Harvard College

Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation

US12297436B2

( en )

2017-05-18

2025-05-13

The Broad Institute, Inc.

Systems, methods, and compositions for targeted nucleic acid editing

WO2018213708A1

( en )

2017-05-18

2018-11-22

The Broad Institute, Inc.

Systems, methods, and compositions for targeted nucleic acid editing

CN118581154A

( en )

2017-06-02

2024-09-03

Genome editing approaches and gene therapy combined with viral vectors for gene therapy of genetic disorders

US11603544B2

( en )

2017-06-05

2023-03-14

Fred Hutchinson Cancer Center

Genomic safe harbors for genetic therapies in human stem cells and engineered nanoparticles to provide targeted genetic therapies

WO2018232195A1

( en )

2017-06-14

2018-12-20

The Broad Institute, Inc.

Compositions and methods targeting complement component 3 for inhibiting tumor growth

WO2018234239A1

( en )

2017-06-19

2018-12-27

Cellectis

ANTI-HBV POLYTHERAPIES INVOLVING SPECIFIC ENDONUCLEASES

WO2018237369A2

( en )

2017-06-23

2018-12-27

Vical Incorporated

LIPID NANOPARTICLE MEDIA ADMINISTRATION OF PLASMIDIC DNA EXPRESSING CRISPR FOR THE TREATMENT OF CHRONIC INFECTION WITH HEPATITIS B VIRUS

CA3064601A1

( en )

2017-06-26

2019-01-03

President And Fellows Of Harvard College

Crispr/cas-adenine deaminase based compositions, systems, and methods for targeted nucleic acid editing

US12049643B2

( en )

2017-07-14

2024-07-30

The Broad Institute, Inc.

Methods and compositions for modulating cytotoxic lymphocyte activity

US12105089B2

( en )

2017-07-17

2024-10-01

The Broad Institute, Inc.

Cell atlas of the healthy and ulcerative colitis human colon

CN111801345A

( en )

2017-07-28

2020-10-20

åä½å¤§å¦çæ ¡é¿åæåä»¬

Methods and compositions for evolutionary base editors using phage-assisted sequential evolution (PACE)

<a href="/p

Delivery, use and therapeutic applications of the crispr-cas systems and … — The Broad Institute, Inc. (US20250381297A1)

Related documents